Biocytogen
IDEAYA Advances Cancer Pipeline with Biocytogen’s Bispecific ADC, Targeting B7H3/PTK7
IDEAYA, Biocytogen, Bispecific ADC, B7H3/PTK7, Cancer Pipeline, Precision Medicine Oncology
IDEAYA Secures $400M Option Deal with Biocytogen for Bispecific ADC
IDEAYA Biosciences, Biocytogen, Bispecific ADC, Option Deal, Cancer Treatment
Ideaya Secures $400M Deal for Biocytogen Bispecific ADC, Aiming to Enhance Drug Combinations
Ideaya Biosciences, Biocytogen, bispecific ADC, drug combinations, $400M deal, biobucks, DNA damage repair molecules